EN DE
STOCK COMPARISON

Sino-Argi Leading Biosciences vs Corteva: Fair Value & Quality

Both stocks run through our valuation models. Here is how Sino-Argi Leading Biosciences (603970) and Corteva (CTVA) compare, as of Sep 25, 2026.

As of Sep 25, 2026, Fair Value Calculator sees Sino-Argi Leading Biosciences as the less overvalued of the two: Sino-Argi Leading Biosciences trades at ¥12.17 versus a fair value of ¥8.32 (-32%), while Corteva trades at $80.42 versus $28.49 (-65%).
Sino-Argi Leading Biosciences
603970.SHG · CNY · Materials
-32%
upside to fair value
overvalued
Price¥12.17
Fair Value¥8.32
Quality57/100
Corteva
CTVA · USD · Materials
-65%
upside to fair value
overvalued
Price$80.42
Fair Value$28.49
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Sino-Argi Leading BiosciencesCorteva
Valuation
18.7×P/E (TTM)43.5×
0.29×P/S (TTM)3.03×
2.08×P/B2.24×
10.7×EV/EBITDA12.4×
n/aPEG1.44×
−31.6%Fair value upside−64.6%
2.6%Dividend yield0.9%
¥0.32Dividend per share$0.72
Profitability
3%Operating margin24%
0.97×EBIT margin trend (5Y)2.56×
11%Return on equity5%
3%Return on assets4%
Growth
5%Revenue growth (YoY)11%
-1.3%Avg. growth/yr (3Y)-0.1%
11.1%Avg. growth/yr (5Y)4.1%
+8.0%Value creation/yr+0.7%
Balance & size
15.1×Interest coverage (EBIT/interest)14.6×
0.06×Debt / equity0.07×
$488MMarket cap$54B
expensiveGrowth qualityhealthy

Sino-Argi Leading Biosciences leads: 10 to 5 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Sino-Argi Leading Biosciencesof which business quality 55 · market factors 53 Cortevaof which business quality 69 · market factors 61
ProfitabilityMargins and returns on capital today
45
30
Quality GrowthAre margins and returns improving?
57
48
CashflowEarnings quality: real cash, not paper profit
13
80
Fin. StrengthBalance sheet, leverage, solvency risk
67
74
InvestmentDisciplined investing over empire-building
90
97
Low VolatilityCalm price path (market factor)
86
84
MomentumPrice trend over the last 3–12 months (market factor)
41
48
52W MomentumDistance to the 52-week high (market factor)
37
59
Net IssuanceShare count: buybacks or dilution?
82
100

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familySino-Argi Leading BiosciencesPrice ¥12.17CortevaPrice $80.42
DCF Models+14%close to the price¥13.91-36%below the price$51.79
Earnings-Based-30%below the price¥8.54-61%below the price$30.99
Dividend Discount-41%below the price¥7.13-88%below the price$9.27
Multiples+3%close to the price¥12.59-56%below the price$35.54
Asset-Based-68%below the price¥3.93-70%below the price$24.19
Growth DCFn/a-25%below the price$60.04
Economic Profit-28%below the price¥8.73-58%below the price$34.06
Growth Earnings-13%close to the price¥10.55-73%below the price$21.85
Minimum-68%below the price¥3.93-88%below the price$9.27
Maximum+14%close to the price¥13.91-25%below the price$60.04
Median-28%below the price¥8.73-60%below the price$32.52
Geometric mean-28%below the price¥8.73-63%below the price$29.49

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Sino-Argi Leading Biosciences: 12 of 17 models see the stock below the current price.

Corteva: 24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Sino-Argi Leading Biosciences
Price ¥12.17
Fair Value ¥8.32
Bear ¥5.20Bull ¥13.17
Corteva
Price $80.42
Fair Value $28.49
Bear $28.08Bull $34.76

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Sino-Argi Leading Biosciences · Materials

Quality score57 · above median
Fair value upside-32% · below median

Corteva · Materials

Quality score70 · Top 25%
Fair value upside-65% · bottom 25%

Bottom line

As of Sep 25, 2026, Fair Value Calculator sees Sino-Argi Leading Biosciences as the less overvalued of the two: Sino-Argi Leading Biosciences trades at ¥12.17 versus a fair value of ¥8.32 (-32%), while Corteva trades at $80.42 versus $28.49 (-65%).

Corteva has the higher quality score (70/100).

Open Sino-Argi Leading Biosciences live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.